Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | MAOA | P21397 | 8/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899464 | 0.85 | GRIA2 (0.46) | GRIA2MAOBMAOASMN1; SMN2HTR6 | |
| SCHEMBL7896587 | 0.85 | GRIA2 (0.46) | GRIA2ATMMAOBMAOASMN1; SMN2 | |
| SCHEMBL7898384 | 0.83 | GRIA2 (0.52) | GRIA2MAOBMAOA | |
| SCHEMBL7898805 | 0.77 | GRIA2 (0.47) | GRIA2HTR6 | |
| SCHEMBL1590737 | 0.75 | GRIA2 (0.54) | GRIA2MAOBMAOA | |
| SCHEMBL1591092 | 0.75 | GRIA2 (0.62) | GRIA2 | |
| SCHEMBL7896403 | 0.74 | GRIA2 (0.52) | GRIA2MAOBMAOA | |
| SCHEMBL7900252 | 0.72 | GRIA2 (0.50) | GRIA2MAOB | |
| SCHEMBL11900094 | 0.72 | GRIA2 (0.52) | GRIA2 | |
| SCHEMBL7898009 | 0.72 | GRIA2 (0.48) | GRIA2MAOBHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | GRIA2 24/4885ATM 2085/4885L3MBTL1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.